Additional file 10 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort
dataset
posted on 2024-08-15, 10:29 authored by I. Vanni, L. Pastorino, V. Andreotti, D. Comandini, G. Fornarini, M. Grassi, A. Puccini, E. T. Tanda, A. Pastorino, V. Martelli, L. Mastracci, F. Grillo, F. Cabiddu, A. Guadagno, S. Coco, E. Allavena, F. Barbero, W. Bruno, B. Dalmasso, S. E. Bellomo, C. Marchiò, F. Spagnolo, S. Sciallero, E. Berrino, P. GhiorzoAdditional file 10. The somatic alterations (VAF ≥ 0.1% and VAF ≥ 0.5% for SNVs/MNVs and InDels, respectively) found in the 23 circulating-free DNAs analyzed in the study. The somatic alterations (coding/nonsynonymous), detected with a VAF ≥ 0.1% for SNVs/MNVs and VAF ≥ 0.5% for InDels, in the 16 tumor tumors analyzed by the TruSight™ Oncology 500 ctDNA panel are shown. For each patient, the somatic alterations were annotated.
